 SAN DIEGO--BUSINESS WIRE--Janux Therapeutics, Inc. Nasdaq: JANX Janux, a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager TRACTr and Tumor Activated Immunomodulator TRACIr platforms, today announced that Janux management will participate in a fireside chat at the virtual H.C. Wainwright BioConnect Conference being held January 10 to 13. The fireside chat will be available for on- 